X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Novartis with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ADCOCK INGRAM (S. Africa) - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   ADCOCK INGRAM
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ADCOCK INGRAM
Jun-14
NOVARTIS/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs758358-   
Low Rs579258-   
Sales per share (Unadj.) Rs228.4106.5-  
Earnings per share (Unadj.) Rs31.7-26.8-  
Cash flow per share (Unadj.) Rs32.8-22.2-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.183.6-  
Shares outstanding (eoy) m24.69168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.9 101.2%   
Avg P/E ratio x21.1-11.5 -183.4%  
P/CF ratio (eoy) x20.4-13.9 -147.3%  
Price / Book Value ratio x2.23.7 61.0%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,50552,027 31.7%   
No. of employees `0000.74.3 15.6%   
Total wages/salary Rs m1,4453,265 44.3%   
Avg. sales/employee Rs Th8,441.34,188.6 201.5%   
Avg. wages/employee Rs Th2,163.6760.6 284.5%   
Avg. net profit/employee Rs Th1,173.1-1,055.4 -111.1%   
INCOME DATA
Net Sales Rs m5,63917,982 31.4%  
Other income Rs m1,718126 1,364.6%   
Total revenues Rs m7,35718,108 40.6%   
Gross profit Rs m-63-3,116 2.0%  
Depreciation Rs m25776 3.3%   
Interest Rs m55487 11.4%   
Profit before tax Rs m1,575-4,253 -37.0%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792266 297.8%   
Profit after tax Rs m784-4,531 -17.3%  
Gross profit margin %-1.1-17.3 6.4%  
Effective tax rate %50.3-6.2 -804.2%   
Net profit margin %13.9-25.2 -55.1%  
BALANCE SHEET DATA
Current assets Rs m9,52213,170 72.3%   
Current liabilities Rs m3,2967,410 44.5%   
Net working cap to sales %110.432.0 344.7%  
Current ratio x2.91.8 162.5%  
Inventory Days Days37111 33.0%  
Debtors Days Days28124 22.9%  
Net fixed assets Rs m467,677 0.6%   
Share capital Rs m12383 147.8%   
"Free" reserves Rs m7,2130-   
Net worth Rs m7,33614,114 52.0%   
Long term debt Rs m04,960 0.0%   
Total assets Rs m11,10526,662 41.7%  
Interest coverage x29.5-7.7 -381.3%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.50.7 75.3%   
Return on assets %7.6-15.2 -49.8%  
Return on equity %10.7-32.1 -33.3%  
Return on capital %22.2-19.8 -112.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-3,5700-   
CASH FLOW
From Operations Rs m1,6101,535 104.9%  
From Investments Rs m687-471 -145.8%  
From Financial Activity Rs m-2,6774,501 -59.5%  
Net Cashflow Rs m-3805,565 -6.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.94 Rs / ZAR

Compare NOVARTIS With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: DR. DATSONS LABS  TORRENT PHARMA  PFIZER  WOCKHARDT  BIOCON   



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views On News

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks (Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock (The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 19, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS